TY - JOUR
T1 - Hallmark discoveries in the biology of Wilms tumour
AU - Perotti, Daniela
AU - Williams, Richard D
AU - Wegert, Jenny
AU - Brzezinski, Jack
AU - Maschietto, Mariana
AU - Ciceri, Sara
AU - Gisselsson, David
AU - Gadd, Samantha
AU - Walz, Amy L
AU - Furtwaengler, Rhoikos
AU - Drost, Jarno
AU - Al-Saadi, Reem
AU - Evageliou, Nicholas
AU - Gooskens, Saskia L
AU - Hong, Andrew L
AU - Murphy, Andrew J
AU - Ortiz, Michael V
AU - O'Sullivan, Maureen J
AU - Mullen, Elizabeth A
AU - van den Heuvel-Eibrink, Marry M
AU - Fernandez, Conrad V
AU - Graf, Norbert
AU - Grundy, Paul E
AU - Geller, James I
AU - Dome, Jeffrey S
AU - Perlman, Elizabeth J
AU - Gessler, Manfred
AU - Huff, Vicki
AU - Pritchard-Jones, Kathy
N1 - © 2023. Springer Nature Limited.
PY - 2023
Y1 - 2023
N2 - The modern study of Wilms tumour was prompted nearly 50 years ago, when Alfred Knudson proposed the 'two-hit' model of tumour development. Since then, the efforts of researchers worldwide have substantially expanded our knowledge of Wilms tumour biology, including major advances in genetics - from cloning the first Wilms tumour gene to high-throughput studies that have revealed the genetic landscape of this tumour. These discoveries improve understanding of the embryonal origin of Wilms tumour, familial occurrences and associated syndromic conditions. Many efforts have been made to find and clinically apply prognostic biomarkers to Wilms tumour, for which outcomes are generally favourable, but treatment of some affected individuals remains challenging. Challenges are also posed by the intratumoural heterogeneity of biomarkers. Furthermore, preclinical models of Wilms tumour, from cell lines to organoid cultures, have evolved. Despite these many achievements, much still remains to be discovered: further molecular understanding of relapse in Wilms tumour and of the multiple origins of bilateral Wilms tumour are two examples of areas under active investigation. International collaboration, especially when large tumour series are required to obtain robust data, will help to answer some of the remaining unresolved questions.
AB - The modern study of Wilms tumour was prompted nearly 50 years ago, when Alfred Knudson proposed the 'two-hit' model of tumour development. Since then, the efforts of researchers worldwide have substantially expanded our knowledge of Wilms tumour biology, including major advances in genetics - from cloning the first Wilms tumour gene to high-throughput studies that have revealed the genetic landscape of this tumour. These discoveries improve understanding of the embryonal origin of Wilms tumour, familial occurrences and associated syndromic conditions. Many efforts have been made to find and clinically apply prognostic biomarkers to Wilms tumour, for which outcomes are generally favourable, but treatment of some affected individuals remains challenging. Challenges are also posed by the intratumoural heterogeneity of biomarkers. Furthermore, preclinical models of Wilms tumour, from cell lines to organoid cultures, have evolved. Despite these many achievements, much still remains to be discovered: further molecular understanding of relapse in Wilms tumour and of the multiple origins of bilateral Wilms tumour are two examples of areas under active investigation. International collaboration, especially when large tumour series are required to obtain robust data, will help to answer some of the remaining unresolved questions.
UR - https://www.mendeley.com/catalogue/6b85fe6c-a9c6-32be-8fb9-4dbfc4d87740/
U2 - 10.1038/s41585-023-00824-0
DO - 10.1038/s41585-023-00824-0
M3 - Article
C2 - 37848532
SN - 1759-4812
JO - Nature reviews. Urology
JF - Nature reviews. Urology
ER -